Gene therapy for homozygous β -thalassemia. Is it a reality?

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Boulad, Farid ^a   Riviére, Isabelle ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gene Therapy; Lentivirus; Stem cell transplantation; Thalassemia

Indexed keywords

BUSULFAN; CD34 ANTIGEN; GLOBIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HEMOGLOBIN BETA CHAIN; IRON; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE PAIN; CAUSE OF DEATH; CHELATION THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DONOR; ERYTHROID CELL; ERYTHROPOIESIS; FATIGUE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC TRANSDUCTION; GLOBIN GENE; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEMATOPOIETIC CELL; HEMOCHROMATOSIS; HEMOLYTIC ANEMIA; HOMOZYGOSITY; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PALLIATIVE THERAPY; PROGENY; REDUCED INTENSITY CONDITIONING; STEM CELL GENE THERAPY; STEM CELL MOBILIZATION; TRANSGENE;

BETA-GLOBINS; BETA-THALASSEMIA; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HOMOZYGOTE; HUMANS; TRANSDUCTION, GENETIC; TRANSPLANTATION CONDITIONING;

LENTIVIRUS;

EID: 73949108653     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903351866     Document Type: Conference Paper

References (25)

1. Weatherall DJ, Clegg JB. The Thalassemia Syndrome. Oxford: Blackwell Scientific; 1981.
2. Stamatoyannopoulos G, Nienhuis AW, Majerus P, Varmus H. The Molecular Basis of Blood Diseases. Philadelphia: WB Saunders; 1994.
3. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245-255.
4. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000; 406:82-86.
5. Borgna-Pignatti C, Rugolotto S, De Stephano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187-1193.
6. Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassaemia. Lancet. 1982;2(8292):227-229.
7. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417-421.
8. Boulad F. Gene therapy for homozygous b-thalassemia In: Kline R, ed. Pediatric Hematopoietic Stem Cell Transplantation. New York: Informa Healthcare; 2006:383-389.
9. Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev. 2002;16:81-85.
10. La Nasa G, Giardini C, Argiolu F, et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood. 2002;99(12):4350-4356.
11. La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian bone marrow transplant group. Ann N Y Acad Sci. 2005;1054:186-195.
12. Gaziev D, Galimberti M, Lucarelli G, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA non-identical sibling or parent transplants. Bone Marrow Transplant. 2000;25(8):815-821.
13. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood. 2002;99:1902-1908.
14. Persons DA, Hargrove PW, Allay ER, Hanawa H, Nienhuis AW. The degree of phenotypic correction of murine beta-thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood. 2003;101:2175-2183.
15. Imren S, Payen E, Westerman KA, et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002;99:14380-14385.
16. Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol. 2006;13:142-148.
17. Rivella S, May C, Chadburn A, Riviere I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood. 2003;101:2932-2939.
18. Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood. 1996;87:3494-3499.
19. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-2413.
20. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401-409.
21. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
22. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9:519-528.
23. Fischer A, Hacein-Bey-Abina S, Lagresle C, et al. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome]. Bull Acad Natl Med. 2005;189:779-785. discussion 786-1778
24. Baum C, Dullmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003;101:2099-2114.
25. Dunbar CE. Stem cell gene transfer: insights into integration and hematopoiesis from primate genetic marking studies. Ann N Y Acad Sci. 2005;1044:178-182.